A Smarter Model For Cancer Therapy

Our cancer therapeutics are built to improve patient outcomes without adding complexity.

Watch our short animated explainer video to understand our technology, below.

Play Video

Built for Patients.

Guided by Biology.

At Jabez, we identify and advance cancer therapeutics that are well-tolerated, affordable to produce, and seamlessly boost the efficacy of current treatment landscapes.

Following our strategic model, we see a path to real clinical progress that doesn’t require overhauling the healthcare system. It just takes some clever thinking, a deep understanding of cancer biology, and deliberate execution.

Discover Our Approach

More About Us

OUR APPROACH

"3-C" Cancer Therapeutics

Our “3‑C” framework is more than a slogan – it’s how every asset is vetted, licensed, and advanced.

Our “3-C” Therapeutics Model:

Convenient

Orally available, outpatient-compatible, patient-friendly.

Cost-Effective

Scalable chemistry, low‑cost manufacturing, global readiness.

Cooperative (Synergistic)

Mechanistically synergistic with standard therapies.

Our 3-C Model

Our Lead Candidate

JBZ-001:

Our Lead Compound

JBZ‑001 is an oral DHODH inhibitor in Phase 1 trials. It’s a proven 3‑C prototype with both single-agent promise and powerful synergy in combination.

It brilliantly exemplifies our 3-C model:

Convenient: Well-tolerated, oral small molecule
Cost-Effective: Leverages Nobel Prize-winning, scalable chemistry
Cooperative: Displays potent synergy with well-established treatment regimens.

Explore JBZ-001

JBZ-001 Clinical Trial

CLINICAL DEVELOPMENT

Our Clinical Trials

Jabez Biosciences is proud to be a clinical-stage biotechnology company. We are currently enrolling patients in a Phase 1 clinical trial evaluating our lead candidate in advanced solid tumors and non-Hodgkin lymphoma.

Learn More About Clinical Trials

Our clinical partners: